banter and General Discussion, page-9147

I know. Crazy isn't it? Sorry got a bit caught up with idiot down-rampers to discuss. But you make a good point, but we should perhaps be a bit more circumspect on overall srGvHD survival rates on Ryconcil at 63% at 100 days vs around 20-30% on Ruxolitinib to which can reportedly often works out to over $1 million in overall treatment costs in srGVHD.

"Cost per CR ranged from US$1,187,657 with ruxolitinib to US$680 with methotrexate."

https://pubmed.ncbi.nlm.nih.gov/29550629/

Funny how we have our readily available, medical expert, doubting Thomas' who despite his courageous and relentless services to mankind, gives us no alternatives to Revascor in treating something responsible for some 25-40% of neo-natal cardiac mortality:

https://www.ncbi.nlm.nih.gov/books/NBK554576/

"Though rare, a diagnosis of HLHS is responsible for 23% of all cardiac deaths in the first week of life."

and lets not forget:

"Reported elective termination of pregnancy after a diagnosis of hypoplastic left heart syndrome varies from 12% to 48%"

The back and forth is so tiresome on these forums as it must be for SI and co. dealing with a similarly obtuse FDA at times.